Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics (MNPR) to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm’s key opinion leader feedback indicates a “heavier commercial” lift than first imagined for Monopar in Wilson disease. A ” higher risk premium to our estimates is warranted here,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
- Monopar Therapeutics reports Q EPS (48c), consensus (40c)
- Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
- Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
- Monopar Therapeutics Unveils Promising Phase 2 Study Results